1. Ministry of Health, Labour, and Welfare (MHLW) of Japan. Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs. Notification No. 9. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan, 1991.
2. International Conference on Harmonization. E5 Guideline: Ethnic Factors in the Acceptability of Foreign Clinical Data (R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf. Published 1998. Accessed June 6, 2016.
3. Ministry of Health, Labour, and Welfare (MHLW) of Japan. Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs. Notification No. 1101001. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan, 2005.
4. Ministry of Health, Labour, and Welfare (MHLW) of Japan. Basic principles on Global Clinical Trials. Notification No. 0928010. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan, 2007.
5. Kawai N, Chuang-Stein C, Komiyama O, Li Y. An Approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Inf J. 2007;42:139–147.